Matt Hill
Matt Hill, Ph.D., is founder and CEO of Elegen Corp., a privately-held company based in the San Francisco Bay Area, committed to revolutionizing genetic medicine and synthetic biology workflows with an innovative cell-free DNA manufacturing technology. Armed with a vision to eliminate the DNA bottleneck at the core of all synthetic biology applications, Hill founded Elegen in 2017 to innovate the DNA build process. Under his direction, the company launched ENFINIA™ DNA in 2023 with industry-leading length, complexity, accuracy, and speed to accelerate discovery for healthcare and pharma as well as agbio and synbio industries. Hill previously served as VP of R&D at Natera, where he co-invented their core technology and led the commercialization of five precision molecular diagnostics products, enabling their successful 2015 IPO. An accomplished scientist, engineer, and entrepreneur with a Ph.D. from Stanford, he is driven to create lasting positive impacts on the world.
Elegen Bio
Reading and Writing: How Far, How Fast, & When?
-
This session will examine the frontiers of genomic sequencing and synthesis, providing a critical assessment of the present capabilities and charting likely trajectories for future progress. Participants will highlight the latest advances in instrumentation, informatics, and automation that are pushing beyond conventional limits, while also considering emerging technologies poised to reshape the landscape of DNA reading and writing. By focusing on accuracy, throughput, and scalability, this discussion will illuminate the fundamental shifts now taking place and the new horizons they open for biological research and innovation.
Conference Pass
2,495
USD
Keynotes & Firesides
Workshops & Breakouts
1:1 Partnering App
Meals & Receptions
Session Recordings
Until Friday April 18th
Full Rate:
$3,495
